Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Abbott Molecular; Roche; Expression Analysis; Source MDx; Sigma-Aldrich, AMDeC; 5AM Solutions; More

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Abbott said this week that its Abbott Molecular business has received the CE Mark for its first DNA sequencing assay developed and introduced by the firm. The Abbott HBV Sequencing test has been developed to identify genomic sequences of the hepatitis B virus. Abbott said that the test is not intended for screening blood donors, plasma, or tissue donors for HBV, or to be used as a diagnostic test to confirm the presence of HBV infection.

Roche this week said that its Cytomegalovirus test has received the CE mark and is commercially available in Europe. The test runs on Roche's Cobas AmpliPrep/Cobas Taqman system. CMV viral load testing helps physicians manage immunocompromised patients at risk for CMV disease. Roche's test, the company said, monitors CMV infections using a system that is easy to use.

Expression Analysis announced this year's recipients of its annual GWAS and Data Analysis grant, under which the winners will each receive 600 Illumina Omni Arrays, and EA will process the arrays and analyze the data at no cost. The winners are Elad Ziv of the University of California, San Francisco, and Chunyan He from Indiana University School of Medicine. The study at UCSF will focus on the genetics of multiple myeloma, and the research at IUMC will focus on integrating genome-wide association and mRNA expression profiling for identification of novel breast cancer susceptibility genes.

Source Precision Medicine, also known as Source MDx, is looking for buyers for 16 molecular diagnostic development programs. Source recently went out of business and assigned its assets to Joseph Finn of accounting firm Finn, Warnke & Gayton for liquidation, which will run the sale on April 29. Among the programs for sale are right programs for a variety of cancers, two programs for infectious diseases, and three programs for autoimmune diseases.

The Sigma Life Science business of Sigma-Aldrich has joined AMDeC's vendor partnership program, under which academic medical research institutes that are members of the consortium can purchase products at a discount. Among the products Sigma will offer through the program are custom oligonucleotide and peptide products.

5AM Solutions said this week that it has signed an agreement to develop next-generation virtual biobanking software for exclusive use by Asterand and its collaborators. Asterand and 5AM will electronically link disparate biobanks to Asterand's centralized biobanking operations in Detroit.

UK-based AMS Biotechnology this week said that it has opened a North American subsidiary, AMSBIO LLC in Orange County, Calif. The subsidiary will provide dedicated sales and service for its research products in North America.

BG Medicine has been included in the Russell 3000 Index, which measures the performance of the 3,000 largest publicly traded companies in the US based on total market capitalization. BG Medicine went public in February.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.